Does the media favor GKOS or GEHC?

In the previous week, Glaukos had 3 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 14 mentions for Glaukos and 11 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 0.82 beat Glaukos' score of 0.76 indicating that GE HealthCare Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GE HealthCare Technologies 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, GKOS or DXCM?

DexCom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 21.51 -$187.69M -$3.25 N/A DexCom $4.66B 7.18 $836.30M $2.53 35.08

Is GKOS or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Glaukos' net margin of -30.68%. DexCom's return on equity of 35.94% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% DexCom 20.12% 35.94% 14.75%

Does the media favor GKOS or DXCM?

In the previous week, Glaukos had 3 more articles in the media than DexCom. MarketBeat recorded 14 mentions for Glaukos and 11 mentions for DexCom. DexCom's average media sentiment score of 1.26 beat Glaukos' score of 0.76 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GKOS or RMD?

ResMed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 21.51 -$187.69M -$3.25 N/A ResMed $5.65B 5.65 $1.52B $10.43 21.13

Is GKOS or RMD more profitable?

ResMed has a net margin of 26.94% compared to Glaukos' net margin of -30.68%. ResMed's return on equity of 25.58% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% ResMed 26.94% 25.58% 18.89%

Does the media favor GKOS or RMD?

In the previous week, ResMed had 2 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for ResMed and 14 mentions for Glaukos. ResMed's average media sentiment score of 1.00 beat Glaukos' score of 0.76 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PHG or GKOS?

Glaukos has a consensus price target of $177.33, indicating a potential downside of 4.17%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Glaukos 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.79

Which has better earnings & valuation, PHG or GKOS?

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Koninklijke Philips $20.17B 1.31 $1.01B $1.36 19.74 Glaukos $507.44M 21.51 -$187.69M -$3.25 N/A

Does the media refer more to PHG or GKOS?

In the previous week, Glaukos had 8 more articles in the media than Koninklijke Philips. MarketBeat recorded 14 mentions for Glaukos and 6 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.81 beat Glaukos' score of 0.76 indicating that Koninklijke Philips is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, GKOS or STE?

STERIS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 21.51 -$187.69M -$3.25 N/A STERIS $5.94B 3.78 $782.30M $8.18 28.10

Is GKOS or STE more profitable?

STERIS has a net margin of 13.34% compared to Glaukos' net margin of -30.68%. STERIS's return on equity of 14.34% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% STERIS 13.34% 14.34% 9.66%

Does the media favor GKOS or STE?

In the previous week, Glaukos had 9 more articles in the media than STERIS. MarketBeat recorded 14 mentions for Glaukos and 5 mentions for STERIS. STERIS's average media sentiment score of 0.86 beat Glaukos' score of 0.76 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Glaukos (GKOS) Competitors

$185.05 +0.52 (+0.28%)

Closing price 08/17/2026 03:58 PM Eastern

Extended Trading

$184.45 -0.60 (-0.32%)

As of 09:19 AM Eastern

Compare

GKOS vs. GEHC, DXCM, RMD, PHG, and STE

Should you buy Glaukos stock or one of its competitors? Glaukos's main competitors and comparable companies include GE HealthCare Technologies (GEHC), DexCom (DXCM), ResMed (RMD), Koninklijke Philips (PHG), and STERIS (STE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Glaukos compare to GE HealthCare Technologies?

Glaukos (NYSE:GKOS) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

GE HealthCare Technologies has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than GE HealthCare Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	21.51	-$187.69M	-$3.25	N/A
GE HealthCare Technologies	$20.63B	1.58	$2.08B	$4.36	16.60

Glaukos presently has a consensus target price of $177.33, suggesting a potential downside of 4.17%. GE HealthCare Technologies has a consensus target price of $77.73, suggesting a potential upside of 7.40%. Given GE HealthCare Technologies' higher probable upside, analysts plainly believe GE HealthCare Technologies is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.48

GE HealthCare Technologies has a net margin of 9.33% compared to Glaukos' net margin of -30.68%. GE HealthCare Technologies' return on equity of 20.12% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
GE HealthCare Technologies	9.33%	20.12%	5.74%

In the previous week, Glaukos had 3 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 14 mentions for Glaukos and 11 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 0.82 beat Glaukos' score of 0.76 indicating that GE HealthCare Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GE HealthCare Technologies	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are owned by institutional investors. 5.9% of Glaukos shares are owned by company insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Glaukos has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, GE HealthCare Technologies has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Summary

GE HealthCare Technologies beats Glaukos on 9 of the 16 factors compared between the two stocks.

How does Glaukos compare to DexCom?

Glaukos (NYSE:GKOS) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

DexCom has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	21.51	-$187.69M	-$3.25	N/A
DexCom	$4.66B	7.18	$836.30M	$2.53	35.08

Glaukos presently has a consensus target price of $177.33, suggesting a potential downside of 4.17%. DexCom has a consensus target price of $88.71, suggesting a potential downside of 0.06%. Given DexCom's stronger consensus rating and higher possible upside, analysts plainly believe DexCom is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

DexCom has a net margin of 20.12% compared to Glaukos' net margin of -30.68%. DexCom's return on equity of 35.94% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
DexCom	20.12%	35.94%	14.75%

In the previous week, Glaukos had 3 more articles in the media than DexCom. MarketBeat recorded 14 mentions for Glaukos and 11 mentions for DexCom. DexCom's average media sentiment score of 1.26 beat Glaukos' score of 0.76 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, DexCom has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Summary

DexCom beats Glaukos on 13 of the 17 factors compared between the two stocks.

How does Glaukos compare to ResMed?

Glaukos (NYSE:GKOS) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Glaukos currently has a consensus price target of $177.33, suggesting a potential downside of 4.17%. ResMed has a consensus price target of $240.17, suggesting a potential upside of 8.98%. Given ResMed's higher probable upside, analysts plainly believe ResMed is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.44

Glaukos has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, ResMed has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

ResMed has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	21.51	-$187.69M	-$3.25	N/A
ResMed	$5.65B	5.65	$1.52B	$10.43	21.13

ResMed has a net margin of 26.94% compared to Glaukos' net margin of -30.68%. ResMed's return on equity of 25.58% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
ResMed	26.94%	25.58%	18.89%

In the previous week, ResMed had 2 more articles in the media than Glaukos. MarketBeat recorded 16 mentions for ResMed and 14 mentions for Glaukos. ResMed's average media sentiment score of 1.00 beat Glaukos' score of 0.76 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 5.9% of Glaukos shares are owned by company insiders. Comparatively, 0.7% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

ResMed beats Glaukos on 10 of the 16 factors compared between the two stocks.

How does Glaukos compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Glaukos (NYSE:GKOS) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Koninklijke Philips has a net margin of 6.30% compared to Glaukos' net margin of -30.68%. Koninklijke Philips' return on equity of 14.38% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	6.30%	14.38%	5.96%
Glaukos	-30.68%	-6.37%	-4.78%

In the previous week, Glaukos had 8 more articles in the media than Koninklijke Philips. MarketBeat recorded 14 mentions for Glaukos and 6 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 0.81 beat Glaukos' score of 0.76 indicating that Koninklijke Philips is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Koninklijke Philips has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Glaukos has a consensus price target of $177.33, indicating a potential downside of 4.17%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

13.7% of Koninklijke Philips shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 5.9% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Koninklijke Philips has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.31	$1.01B	$1.36	19.74
Glaukos	$507.44M	21.51	-$187.69M	-$3.25	N/A

Summary

Koninklijke Philips and Glaukos tied by winning 8 of the 16 factors compared between the two stocks.

How does Glaukos compare to STERIS?

Glaukos (NYSE:GKOS) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

STERIS has a net margin of 13.34% compared to Glaukos' net margin of -30.68%. STERIS's return on equity of 14.34% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
STERIS	13.34%	14.34%	9.66%

In the previous week, Glaukos had 9 more articles in the media than STERIS. MarketBeat recorded 14 mentions for Glaukos and 5 mentions for STERIS. STERIS's average media sentiment score of 0.86 beat Glaukos' score of 0.76 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, STERIS has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

99.0% of Glaukos shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 5.9% of Glaukos shares are held by insiders. Comparatively, 1.1% of STERIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

STERIS has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	21.51	-$187.69M	-$3.25	N/A
STERIS	$5.94B	3.78	$782.30M	$8.18	28.10

Glaukos currently has a consensus price target of $177.33, suggesting a potential downside of 4.17%. STERIS has a consensus price target of $271.33, suggesting a potential upside of 18.04%. Given STERIS's higher probable upside, analysts plainly believe STERIS is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

STERIS beats Glaukos on 10 of the 16 factors compared between the two stocks.

Get Glaukos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GKOS vs. The Competition

Export

Metric	Glaukos	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$10.88B	$5.89B	$7.03B	$24.32B
Dividend Yield	N/A	1.75%	2.56%	3.69%
P/E Ratio	-56.94	26.51	270.85	30.50
Price / Sales	21.51	65.14	579.15	20.15
Price / Cash	N/A	33.83	28.87	20.48
Price / Book	16.20	6.03	11.08	4.92
Net Income	-$187.69M	$148.46M	$3.45B	$1.07B
7 Day Performance	1.14%	-0.26%	0.61%	0.13%
1 Month Performance	17.89%	4.26%	2.08%	2.60%
1 Year Performance	106.84%	8.11%	61.61%	18.42%

Glaukos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GKOS Glaukos	2.25 of 5 stars	$185.05 +0.3%	$177.33 -4.2%	+105.8%	$10.88B	$507.44M	N/A	1,094
GEHC GE HealthCare Technologies	4.4567 of 5 stars	$72.94 +1.6%	$77.73 +6.6%	-1.4%	$32.42B	$20.63B	16.73	54,000
DXCM DexCom	4.3305 of 5 stars	$87.65 +3.4%	$88.71 +1.2%	+9.6%	$31.98B	$4.66B	34.64	11,000
RMD ResMed	4.1686 of 5 stars	$220.06 +3.8%	$240.17 +9.1%	-22.6%	$30.74B	$5.65B	21.10	10,600
PHG Koninklijke Philips	2.8404 of 5 stars	$26.92 +0.7%	N/A	-2.3%	$26.27B	$20.17B	19.84	65,340	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GKOS) was last updated on 8/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glaukos (GKOS) Competitors

GKOS vs. GEHC, DXCM, RMD, PHG, and STE

How does Glaukos compare to GE HealthCare Technologies?

Summary

How does Glaukos compare to DexCom?

Summary

How does Glaukos compare to ResMed?

Summary

How does Glaukos compare to Koninklijke Philips?

Summary

How does Glaukos compare to STERIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Glaukos (GKOS) Competitors

GKOS vs. GEHC, DXCM, RMD, PHG, and STE

How does Glaukos compare to GE HealthCare Technologies?

Which has stronger valuation & earnings, GKOS or GEHC?

Do analysts rate GKOS or GEHC?

Is GKOS or GEHC more profitable?

Does the media favor GKOS or GEHC?

Do insiders & institutionals hold more shares of GKOS or GEHC?

Which has more risk & volatility, GKOS or GEHC?

Summary

How does Glaukos compare to DexCom?

Do institutionals & insiders hold more shares of GKOS or DXCM?

Which has preferable valuation and earnings, GKOS or DXCM?

Do analysts rate GKOS or DXCM?

Is GKOS or DXCM more profitable?

Does the media favor GKOS or DXCM?

Which has more volatility and risk, GKOS or DXCM?

Summary

How does Glaukos compare to ResMed?

Do analysts prefer GKOS or RMD?

Which has more risk and volatility, GKOS or RMD?

Which has preferable earnings and valuation, GKOS or RMD?

Is GKOS or RMD more profitable?

Does the media favor GKOS or RMD?

Do institutionals and insiders hold more shares of GKOS or RMD?

Summary

How does Glaukos compare to Koninklijke Philips?

Is PHG or GKOS more profitable?

Does the media refer more to PHG or GKOS?

Which has more risk and volatility, PHG or GKOS?

Do analysts rate PHG or GKOS?

Do institutionals & insiders have more ownership in PHG or GKOS?

Which has better earnings & valuation, PHG or GKOS?

Summary

How does Glaukos compare to STERIS?

Is GKOS or STE more profitable?

Does the media favor GKOS or STE?

Which has more volatility & risk, GKOS or STE?

Do insiders and institutionals hold more shares of GKOS or STE?

Which has better valuation and earnings, GKOS or STE?

Do analysts recommend GKOS or STE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GKOS vs. The Competition

Glaukos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools